TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27488238

Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (self-reported intake of fruit, vegetables, nuts, legumes, whole grains, fish, red meat, monounsaturated fat:saturated fat ratio, and alcohol)
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Mediterranean diet score
Number of subjects: 4497
Study: 27488509

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 82
Study: 27488552

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including BP screening and home health education by trained community health workers (CHWs); providers trained in hypertension management; compensation of CHWs for additional services.
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) for individuals with uncontrolled hypertension at baseline.
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Stakeholder support for MCI strategies.
Number of subjects: 412
Study: 27488566

Group type: EXPERIMENTAL
Intervention: Integrated electronic Diagnosis Approach (IeDA) - an electronic IMCI protocol provided to nurses
Number of subjects: 0
Study: 27488722

Group type: EXPERIMENTAL
Intervention: PECARN clinical decision rule
Number of subjects: 1499
Study: 27488898

Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of BMI1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bmi1 haploinsufficiency
Number of subjects: 0
Study: 27489076

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27489204

Group type: EXPERIMENTAL
Intervention: Videoconferencing group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Face-to-Face (F2F) group
Number of subjects: 107
Study: 27489247

Group type: EXPERIMENTAL
Intervention: My Mobile Advice Program (MyMAP) smoking cessation program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard self-help program
Number of subjects: 66
Study: 27490698

Group type: EXPERIMENTAL
Intervention: New Shigella vaccine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Licensed vaccines
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vaccine recipients with neutropenia
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subjects of African descent
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: General findings from literature review
Number of subjects: 5
Study: 27490919

Group type: EXPERIMENTAL
Intervention: Roux-en-y bypass (RYGB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 30
Study: 27491288

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention plus treatment as usual (experimental group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 120
Study: 27491485

Group type: EXPERIMENTAL
Intervention: Self-expanding transcatheter aortic valve replacement (TAVR)
Number of subjects: 3578
Study: 27491487

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27491548

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance vector analysis (BIVA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 22
Study: 27492005

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 43
Study: 27492508

Group type: EXPERIMENTAL
Intervention: Ventilator-integrated end-tidal CO2 (ETCO2) monitoring
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 (TcCO2) monitoring
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ETCO2 and TcCO2 monitoring
Number of subjects: 28
Study: 27492535

Group type: EXPERIMENTAL
Intervention: Asthma control
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma predictors
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Protection from uncontrolled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Predictors of uncontrolled disease
Number of subjects: 203
Study: 27492790

Group type: EXPERIMENTAL
Intervention: Universal decolonization using intranasal mupirocin and chlorhexidine bath (2 cycles, 1 month apart)
Number of subjects: 16773

Group type: EXPERIMENTAL
Intervention: On-site MRSA surveillance with targeted decolonization
Number of subjects: 16773
Study: 27492881

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (brachial plexus block [BPB] with 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Local anaesthesia (0.5% L-bupivacaine and 1% lidocaine injected subcutaneously)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (BPB)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 126
Study: 27493133

Group type: EXPERIMENTAL
Intervention: Gather mHealth System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27493790

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times a day
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times a day
Number of subjects: 956

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 956
Study: 27493796

Group type: EXPERIMENTAL
Intervention: Thyroid-associated ophthalmopathy (TAO) group
Number of subjects: 66
Study: 27494163

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (2 doses, liquid formulation, separated by ≥4 weeks)
Number of subjects: 3040
Study: 27494911

Group type: EXPERIMENTAL
Intervention: Decolonization therapy with oral aminoglycosides (gentamicin and neomycin/streptomycin)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Gentamicin oral therapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Neomycin/streptomycin therapy
Number of subjects: 77
Study: 27495056

Group type: EXPERIMENTAL
Intervention: Belief in the harm of high salt intake
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Healthy salt intake behavior
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Years in school
Number of subjects: 4693

Group type: EXPERIMENTAL
Intervention: Knowledge of salt intake
Number of subjects: 4693
Study: 27495287

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 20
Study: 27495290

Group type: EXPERIMENTAL
Intervention: Moderate frequency of coffee intake
Number of subjects: 992
Study: 27495743

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (10 °C, left hand) as conditioning stimulus (CS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Heat pain (43-49 °C, pain intensity 60 ± 5 on the 101-point numeric rating scale, right forearm) as test stimulus (TS)
Number of subjects: 25
Study: 27495752

Group type: EXPERIMENTAL
Intervention: Extravascular lung water (EVLWi)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PaO2/FiO2 ratio
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 47
Study: 27495955

Group type: EXPERIMENTAL
Intervention: Fermented red ginseng
Number of subjects: 15
Study: 27495959

Group type: EXPERIMENTAL
Intervention: Ultrasound visualization of the axillary vein
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound visualization of the subclavian vein
Number of subjects: 50
Study: 27496260

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 110
Study: 27496264

Group type: EXPERIMENTAL
Intervention: Cushing syndrome patients before surgery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cushing syndrome patients after surgery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cushing syndrome patients
Number of subjects: 54
Study: 27496270

Group type: EXPERIMENTAL
Intervention: BMI categorization for identifying excess adiposity
Number of subjects: 10465

Group type: EXPERIMENTAL
Intervention: Excess adiposity cutpoints (75th, 85th, 90th percentiles of DXA body fat)
Number of subjects: 10465

Group type: EXPERIMENTAL
Intervention: Presence of excess adiposity
Number of subjects: 10465

Group type: EXPERIMENTAL
Intervention: BMI categorization
Number of subjects: 10465
Study: 27496276

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound measurement of skin thickness
Number of subjects: 0
Study: 27496798

Group type: EXPERIMENTAL
Intervention: Autoantibody positive subjects (auto-AB+)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Wilson disease
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Known diagnoses other than AIH
Number of subjects: 986
Study: 27496946

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25-OHD <25 nmol/l)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Normal vitamin D levels (25-OHD >75 nmol/l)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Low ionized calcium (Ca(2+))
Number of subjects: 1248
Study: 27497181

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging method
Number of subjects: 99

Group type: COMPARATOR
Intervention: Blue dye method
Number of subjects: 99
Study: 27497862

Group type: EXPERIMENTAL
Intervention: CTX-DP (2 million, 5 million, 10 million, or 20 million cells by stereotactic ipsilateral putamen injection)
Number of subjects: 11
Study: 27498122

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE) for assessing right ventricular (RV) dysfunction
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Presence of ≥1 echocardiographic signs of RV dysfunction
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Presence of ≥2 echocardiographic signs of RV dysfunction
Number of subjects: 400
Study: 27499218

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Lean body mass (LBM)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Early transmitral flow velocity to early mitral annular velocity
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Left atrial internal diameter
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: TAPSE
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: LBM
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 233
Study: 27499222

Group type: EXPERIMENTAL
Intervention: Pre-procedural unfractioned heparin
Number of subjects: 5997

Group type: EXPERIMENTAL
Intervention: Pre-procedural 600mg clopidogrel loading dose
Number of subjects: 5997

Group type: COMPARATOR
Intervention: No-reflow
Number of subjects: 5997
Study: 27499309

Group type: EXPERIMENTAL
Intervention: Most active accelerometry quartile (25 minutes/week of moderate to vigorous physical activity, 2,150 steps/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lowest activity quartile (less than 5 min/week of MVPA, fewer than 460 steps/day)
Number of subjects: 65
Study: 27499694

Group type: EXPERIMENTAL
Intervention: E/E' ratio goal-directed therapy in kidney recipients with baseline diastolic dysfunction
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: E/E' ratio
Number of subjects: 242
Study: 27499948

Group type: EXPERIMENTAL
Intervention: Second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-use group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-use group
Number of subjects: 0
Study: 27499979

Group type: EXPERIMENTAL
Intervention: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.2 mg/kg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.6 mg/kg
Number of subjects: 2
Study: 27500326

Group type: EXPERIMENTAL
Intervention: African American women
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Initial hCG values < 1,500
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Initial hCG values 1,500-3,000
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Initial hCG values > 3,000
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Prior miscarriage
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Presentation of bleeding
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Presentation of pain
Number of subjects: 285
Study: 27500329

Group type: EXPERIMENTAL
Intervention: Second uterine curettage
Number of subjects: 60
Study: 27501514

Group type: EXPERIMENTAL
Intervention: Initial form of periodontal care
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (periodontally healthy)
Number of subjects: 27
Study: 27501608

Group type: EXPERIMENTAL
Intervention: Postoperative Epidural Analgesia
Number of subjects: 364
Study: 27501618

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 152
Study: 27501792

Group type: EXPERIMENTAL
Intervention: Vortical blood flow estimation method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortex-based estimation of elevated mPAP
Number of subjects: 0
Study: 27502121

Group type: EXPERIMENTAL
Intervention: Stable heart failure with reduced ejection fraction (≤40%)
Number of subjects: 5276
Study: 27502603

Group type: EXPERIMENTAL
Intervention: T2* dynamic-susceptibility contrast MRI (DSC-MRI) and diffusion-weighted imaging (DWI) before radiotherapy and every 2 months thereafter until relapse.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Voxels thresholded for hyperperfused areas using a 1.75 fixed rCBV threshold.
Number of subjects: 44
Study: 27502708

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg PO b.i.d. d1-d7 every 21 days
Number of subjects: 72
Study: 27502712

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 123
Study: 27502759

Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation Intervention (IMMI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Access to Guided Meditation
Number of subjects: 44
Study: 27502768

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed
Number of subjects: 427

Group type: COMPARATOR
Intervention: Exclusively formula-fed
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Mixed-fed
Number of subjects: 427
Study: 27502804

Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Land-based exercise (LBE)
Number of subjects: 25
Study: 27502866

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study: 27502928

Group type: EXPERIMENTAL
Intervention: Azithromycin or Doxycycline (exact dosage and duration not specified)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-collection of anorectal and vaginal swabs before treatment and at weeks 1, 2, 4, 6, 8, 10, and 12
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Logistic regression models assessing impact of sexual exposure and alternate anatomic site of infection
Number of subjects: 400
Study: 27503501

Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 96
Study: 27503642

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (single 2-h intravenous infusion); cohort 1: 2,000 to 500 mg; cohort 2: 2,000 to 500 mg [≥40 kg] or 50 to 12.5 mg/kg [<40 kg]; cohorts 3 and 4: 50 to 12.5 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 32
Study: 27504001

Group type: EXPERIMENTAL
Intervention: Tricuspid aortic valve (TAV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve (BAV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TAV in younger patients (<72 years old)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TAV in older patients (≥72 years old)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: BAV in younger patients (<51 years old)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: BAV in older patients (≥51 years old)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AVCd
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 200
Study: 27504002

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 10568

Group type: COMPARATOR
Intervention: DAPT interruption
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 10568
Study: 27504087

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 1
Study: 27504630

Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (IgM-IVIg) (5 mg/kg/d over three days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 27504830

Group type: EXPERIMENTAL
Intervention: Family history of stroke (FH+)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Family history of coronary heart disease (FH+ CHD)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Family history of peripheral artery disease (FH+ PAD)
Number of subjects: 382
Study: 27506223

Group type: EXPERIMENTAL
Intervention: Smartphone application for insulin titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 27506279

Group type: EXPERIMENTAL
Intervention: Parental or caretaker assistance in stool sampling initiation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Parental assistance in placement of stool in the container
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Teenagers' feelings about stool sampling
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Role of parents or caretakers in stool sampling
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Autonomy in stool sampling
Number of subjects: 72
Study: 27506432

Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE) for rectal cancer
Number of subjects: 545
Study: 27507113

Group type: EXPERIMENTAL
Intervention: Lysine chloride supplementation (115 mmol/d for 3 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Hypochloremia (chloride ≤96 mmol/L)
Number of subjects: 172
Study: 27507156

Group type: EXPERIMENTAL
Intervention: Patients with atypical femur fractures (AFF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control patients taking long term bisphosphonates
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atypical femur fracture patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both cohorts (AFF and control)
Number of subjects: 23
Study: 27507228

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 38
Study: 27507877

Group type: EXPERIMENTAL
Intervention: Selinexor (30 mg/m²) in combination with fludarabine and cytarabine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fludarabine and Cytarabine (without Selinexor)
Number of subjects: 18
Study: 27508494

Group type: EXPERIMENTAL
Intervention: Childhood pneumonia cases (843)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Lifetime pneumonia cases (3,766)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control subjects for childhood pneumonia (9,091)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control subjects for lifetime pneumonia (5,659)
Number of subjects: 843
Study: 27509100

Group type: EXPERIMENTAL
Intervention: Thymectomy plus alternate-day prednisone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 126
Study: 27509385

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33.0°C (hypothermia)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Targeted temperature management at 36.8°C (normothermia)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Hospital discharge Pediatric Cerebral Performance Category scores
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Three-month Vineland Adaptive Behavior Scale scores
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 295
Study: 27510328

Group type: EXPERIMENTAL
Intervention: fMRI data quality assessment plot
Number of subjects: 0
Study: 27510535

Group type: EXPERIMENTAL
Intervention: Fish-oil therapy
Number of subjects: 182
Study: 27512620

Group type: EXPERIMENTAL
Intervention: Ester-C(®) (EC, 1000 mg vitamin C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PL, 0 mg vitamin C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ascorbic acid (AA, 1000 mg vitamin C)
Number of subjects: 36
Study: 27512970

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: non-HDL cholesterol
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: total cholesterol
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: apolipoprotein B
Number of subjects: 7641
Study: 27514314

Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation treatment
Number of subjects: 0
Study: 27514463

Group type: EXPERIMENTAL
Intervention: Statin therapy guided by pharmacogenetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard statin therapy without pharmacogenetic guidance
Number of subjects: 0
Study: 27514750

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) in ROSE
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) in DOSE
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Development of WHF between baseline to 24 hours
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Development of WHF between 24 to 48 hours
Number of subjects: 668
Study: 27515038

Group type: EXPERIMENTAL
Intervention: Breathing through a facemask with 7.5 cmH2O inspiratory and/or expiratory resistors
Number of subjects: 13
Study: 27515128

Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy (AAC) with 1.5% acetic acid instillation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy (AAC)
Number of subjects: 126